

## PRIMARY SERIES Recommendations

### IMMUNOCOMPETENT INDIVIDUALS

Age	Important Notes	Recommended Intervals	Minimum Intervals
<b>12-29 years</b>  (Pfizer or Moderna*)	<p style="text-align: center;"><b>Preference:</b> Monovalent Pfizer-BioNTech (30 mcg, Grey Cap)</p> <hr style="border-top: 1px dotted black;"/> <p>* <b>Moderna (100 mcg)</b> can be administered if requested with informed consent regarding increased risk of myocarditis/pericarditis.</p>	<p><b>Primary Series:</b></p> <ul style="list-style-type: none"> <li>• 1<sup>st</sup> dose</li> <li>• 2<sup>nd</sup> dose (56 days after 1<sup>st</sup>)</li> </ul>	<p><b>Primary Series:</b></p> <ul style="list-style-type: none"> <li>• 1<sup>st</sup> dose</li> <li>• 2<sup>nd</sup> dose (28 days after 1<sup>st</sup>)</li> </ul>
<b>30+ years</b> (Pfizer or Moderna)	<p style="text-align: center;"><b>NO PREFERENCE</b></p> <p style="text-align: center;"><b>Monovalent Pfizer-BioNTech (30 mcg, Grey Cap)</b></p> <p style="text-align: center;">OR</p> <p style="text-align: center;"><b>Monovalent Moderna (100 mcg)</b></p>	<p><b>Primary Series:</b></p> <ul style="list-style-type: none"> <li>• 1<sup>st</sup> dose</li> <li>• 2<sup>nd</sup> dose (56 days after 1<sup>st</sup>)</li> </ul>	<p><b>Primary Series:</b></p> <ul style="list-style-type: none"> <li>• 1<sup>st</sup> dose</li> <li>• 2<sup>nd</sup> dose (28 days after 1<sup>st</sup>)</li> </ul>

### IMMUNOCOMPROMISED INDIVIDUALS ONLY

Age	Important Notes	Recommended Intervals	Minimum Intervals
<b>12-29 years</b>  (Pfizer or Moderna*)	<p style="text-align: center;"><b>Preference:</b> Monovalent Pfizer-BioNTech (30 mcg, Grey Cap)</p> <hr style="border-top: 1px dotted black;"/> <p>* <b>Moderna (100 mcg)</b> can be administered if requested with informed consent regarding increased risk of myocarditis/pericarditis.</p>	<p><b>Primary Series:</b></p> <ul style="list-style-type: none"> <li>• 1<sup>st</sup> dose</li> <li>• 2<sup>nd</sup> dose (56 days after 1<sup>st</sup>)</li> <li>• 3<sup>rd</sup> dose (56 days after 2<sup>nd</sup>)</li> </ul>	<p><b>Primary Series:</b></p> <ul style="list-style-type: none"> <li>• 1<sup>st</sup> dose</li> <li>• 2<sup>nd</sup> dose (28 days after 1<sup>st</sup>)</li> <li>• 3<sup>rd</sup> Dose 28 days after 2<sup>nd</sup></li> </ul>
<b>30+ years</b> (Pfizer or Moderna)	<p style="text-align: center;"><b>NO PREFERENCE</b></p> <p style="text-align: center;"><b>Monovalent Pfizer-BioNTech (30 mcg, Grey Cap)</b></p> <p style="text-align: center;">OR</p> <p style="text-align: center;"><b>Monovalent Moderna (100 mcg)</b></p>	<p><b>Primary Series:</b></p> <ul style="list-style-type: none"> <li>• 1<sup>st</sup> dose</li> <li>• 2<sup>nd</sup> dose (56 days after 1<sup>st</sup>)</li> <li>• 3<sup>rd</sup> dose (56 days after 2<sup>nd</sup>)</li> </ul>	<p><b>Primary Series:</b></p> <ul style="list-style-type: none"> <li>• 1<sup>st</sup> dose</li> <li>• 2<sup>nd</sup> dose (28 days after 1<sup>st</sup>)</li> <li>• 3<sup>rd</sup> Dose 28 days after 2<sup>nd</sup></li> </ul>

For information outlining the criteria for moderately to severely immunocompromised, see the *Primary Series Recommendations for Moderately to Severely Immunocompromised Individuals* section in the [COVID-19 Vaccine Guidance](#) document.

## BOOSTER DOSE Recommendations

Age	Important Notes	Recommended Intervals	Minimum Intervals
12 to 17 years (Bivalent Pfizer)	<p><b>Preference:</b> BIVALENT Pfizer-BioNTech (30 mcg)</p>	<p><b>Booster Doses:</b></p> <ul style="list-style-type: none"> <li>168 days after last dose</li> </ul>	<p><b>Booster Doses:</b></p> <ul style="list-style-type: none"> <li>84 days after last dose</li> </ul>
	<p><b>* Monovalent Pfizer (30mcg, Grey Cap) can be administered if requested.</b></p>		
18+ years (Bivalent Pfizer or Moderna)	<p><b>Preference:</b> Bivalent mRNA vaccine</p> <p><b>Bivalent Pfizer-BioNTech (30 mcg)</b> contains Omicron BA.4/5</p> <p style="text-align: center;">OR</p> <p><b>Bivalent Moderna (50 mcg)</b> Contains Omicron BA.1</p>	<p><b>Booster Doses:</b></p> <ul style="list-style-type: none"> <li>168 days after last dose</li> </ul>	<p><b>Booster Doses:</b></p> <ul style="list-style-type: none"> <li>84 days after last dose</li> </ul>
	<p><b>* Monovalent Moderna (50 mcg) or Monovalent Pfizer (30mcg) can be administered if requested with informed consent.</b></p>		
	<p><b>* 70+ Monovalent Moderna (100 mcg) or Monovalent Pfizer (30mcg) can be administered if requested with informed consent.</b></p>		

Other Recommendations	
<b>Co-Administration</b>	<p>Individuals 6 months and older, may receive a COVID-19 vaccine simultaneously with (i.e., same day), or at any time before or after non-COVID-19 vaccines (including live and non-live vaccines). Informed consent should include a discussion of the benefits and risks given the limited data available on administration of COVID-19 vaccines at the same time as, or shortly before or after, other vaccines. <a href="#">COVID-19 Vaccine Guidance</a>, Version 4.0</p>
<b>Suggested Interval Between Previous SARS-CoV-2 Infection and COVID-19 Vaccination</b>	<p><b>Infection Prior to Completion of Primary Series</b></p> <ul style="list-style-type: none"> <li><b>≥6 months, Immunocompetent &amp; no history of MIS-C in children:</b> 2 months (56 days) after symptom onset or positive test if asymptomatic</li> <li><b>≥6 months, Immunocompromised &amp; no history of MIS-C following vaccination:</b> 1-2 months (28-56 days) after symptom onset or positive test if asymptomatic</li> <li><b>≥6 months &amp; previous history of MIS-C following vaccination (immunocompetent or immunocompromised):</b> Receive vaccine when clinic recovery has been achieved or ≥90days since onset of MIS-C, whichever is longer.</li> </ul> <p><b>Infection After Primary Series</b></p> <ul style="list-style-type: none"> <li><b>Individuals Eligible for Booster Dose(s):</b> A 6-month (168 day) interval is recommended and may provide a better immune response, however, a minimum interval of 3 months (84 days) after symptom onset or positive test (if asymptomatic) may be considered in the context of heightened epidemiologic risk, as well as operational considerations for the efficient deployment of vaccine programs (NACI, 2022)</li> </ul>